Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Tti-101
Idiopathic Pulmonary Fibrosis
Phase II
Completed
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Jan 03, 2023
―
Pembrolizumab, Bevacizumab, Atezolizumab, Tti-101
Hepatocellular Carcinoma
Phase I/II
Recruiting
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Jun 27, 2022
―
Fulvestrant, Palbociclib, Ribociclib, Aromatase Inhibitor (Ai), Tti-101
Breast Cancer
Phase I
Terminated
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
May 17, 2022
―
Tti-101
Melanoma, Colorectal Cancer, Breast Cancer, Non Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Advanced Cancer, Gastric Adenocarcinoma, Hepatocellular Cancer
Phase I
Completed
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Jun 09, 2017
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Tvardi Therapeutics (TVRD) have in its pipeline
TVRD is currently developing the following drugs: Tti-101, Pembrolizumab, Bevacizumab, Atezolizumab, Tti-101, Fulvestrant, Palbociclib, Ribociclib, Aromatase Inhibitor (Ai), Tti-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.